The TOGETHER Project - Kidney RNA-seq Validation

Completed

• Conditions: Kidney Transplant Rejection

• Registration Number: NCT03874299
• Lead Sponsor: Mayo Clinic

Brief Summary

The researchers are trying to develop a way to measure the risk of rejection through the validation of a blood test.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11-17
• Study First Submitted: 2019-03-12
• Study First Submitted QC: 2019-03-12
• Study First Posted: 2019-03-14
• Primary Completion: 2019-06-20
• Study Completion: 2019-06-20
• Status Verified: 2022-09
• Last Update Submitted: 2022-09-15
• Last Update Posted: 2022-09-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 302

Inclusion Criteria

• Adult (>/=18 years) renal transplant recipient.
• Patients who have given informed consent and are willing to comply with the protocol, including the use of their peripheral blood specimens and data for subsequent research.

Exclusion Criteria

-Adult (<18 years) renal transplant recipient.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To validate the use of a RNA-seq based peripheral blood assay in renal transplant recipients.	3 years	The study will validate the ability of a peripheral blood assay to assess the risk of biopsy proven rejection.

Trial Locations

Locations (1)

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States